Meral Beksaç

Active 2000–2026

Also published as
Meral Beksac
124
Papers
27,248
Citations
69
h-index
111
i10-index

Citations

Citations per year for Meral Beksaç1948: 1 citations1988: 1 citations1989: 1 citations1990: 1 citations1993: 1 citations1994: 1 citations2000: 1 citations2002: 2 citations2003: 3 citations2004: 6 citations2005: 10 citations2006: 13 citations2007: 23 citations2008: 45 citations2009: 45 citations2010: 56 citations2011: 84 citations2012: 127 citations2013: 150 citations2014: 168 citations2015: 163 citations2016: 232 citations2017: 237 citations2018: 188 citations2019: 827 citations2020: 914 citations2021: 1,034 citations2022: 772 citations2023: 541 citations2024: 1,049 citations2025: 501 citations2026: 15 citations1949–1987: no citations, so these years are not shown1991–1992: no citations, so these years are not shown1995–1999: no citations, so these years are not shown2001: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,110 citing papers, 21.5% of this breakdownChina: 667 citing papers, 6.8% of this breakdownItaly: 607 citing papers, 6.2% of this breakdownGermany: 602 citing papers, 6.1% of this breakdownUnited Kingdom: 562 citing papers, 5.7% of this breakdownFrance: 540 citing papers, 5.5% of this breakdownSpain: 533 citing papers, 5.4% of this breakdownNetherlands: 345 citing papers, 3.5% of this breakdownCanada: 329 citing papers, 3.3% of this breakdownGreece: 318 citing papers, 3.2% of this breakdownAustralia: 271 citing papers, 2.8% of this breakdownBelgium: 216 citing papers, 2.2% of this breakdown
0%21.5%Other 27.8%

Fields

  • Medicine75%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Immunology and Microbiology3.4%
  • Computer Science2%
  • Engineering0.5%
  • Social Sciences0.3%
  • Other1.6%

Topics

  • Multiple Myeloma Research and Treatments21.3%
  • Protein Degradation and Inhibitors9.1%
  • Peptidase Inhibition and Analysis5.5%
  • CAR-T cell therapy research3.1%
  • Cancer Treatment and Pharmacology3.1%
  • Amyloidosis: Diagnosis, Treatment, Outcomes2.7%
  • Other55.2%

Coauthors

All papers

Open in search
  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  2. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 cited by 515

  3. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin Song, Timon Hansen, Salomon Manier, Wilfried Roeloffzen, Krzysztof Jamroziak, Fiona Kwok, Chihiro Shimazaki, Jin Seok Kim, Edvan Crusoé, Tahamtan Ahmadi, NamPhuong Tran, Xiang Qin, Sandra Y. Vasey, Brenda Tromp, Jordan M. Schecter, Brendan M. Weiss, Sen Hong Zhuang, Jessica Vermeulen, Giampaolo Merlini, Raymond L. Comenzo - New England Journal of Medicine 2021 cited by 668

  4. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  5. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,513

  6. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  7. International uniform response criteria for multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the International Myeloma Working Group - Leukemia 2006 cited by 2,639

  8. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 cited by 327

  9. Extramedullary disease in multiple myeloma: a systematic literature review

    Authors: , , , , , , , , , , - Blood Cancer Journal 2022 cited by 278

  10. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 151

  11. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,320

  12. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose and 65 more - The Lancet Oncology 2019 cited by 385

  13. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 243

  14. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  15. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA

    Authors: , , , , , , , , , , , , , - Journal of Hematology & Oncology 2021 cited by 176

  16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 cited by 114

  17. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L. Kaufman, Enrique M. Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Claudia Corrado, B. Bengoudifa, Florence Binlich, Paul G. Richardson - The Lancet Oncology 2014 cited by 788

  18. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark‐David Levin, Gerard M.J. Bos, Heinz Ludwig, Sara Aquino, Anna Morelli, Ka Lung Wu, Rinske Boersma, Roman Hájek, Marc Durian, Peter A. von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf‐Henrik Mellqvist, Marinus van Marwijk Kooy, Monique C. Minnema, Caroline M.P.W. Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld - The Lancet Haematology 2020 cited by 384

  19. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 160

  20. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 120

  21. Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Saad Z. Usmani, Karin Vanderkerken, David H. Vesole, Anders Waage, Sonja Zweegman, Paul G. Richardson, Joan Bladé - British Journal of Haematology 2021 cited by 174

  22. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 121

  23. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354

  24. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

    Authors: , , , , , , , , , , , , , , , - Molecular Cancer 2021 cited by 74